Notice: Trading of Ikena Oncology halted at 08:25 AM EST due to "News pending". Ikena Oncology (IKNA) Competitors $1.67 +0.12 (+7.74%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IKNA vs. VALN, LRMR, FHTX, CCCC, IMMP, FDMT, CMPS, BNTC, ACIU, and AMLXShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Valneva (VALN), Larimar Therapeutics (LRMR), Foghorn Therapeutics (FHTX), C4 Therapeutics (CCCC), Immutep (IMMP), 4D Molecular Therapeutics (FDMT), COMPASS Pathways (CMPS), Benitec Biopharma (BNTC), AC Immune (ACIU), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Ikena Oncology vs. Valneva Larimar Therapeutics Foghorn Therapeutics C4 Therapeutics Immutep 4D Molecular Therapeutics COMPASS Pathways Benitec Biopharma AC Immune Amylyx Pharmaceuticals Valneva (NASDAQ:VALN) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation. Does the media refer more to VALN or IKNA? In the previous week, Valneva had 1 more articles in the media than Ikena Oncology. MarketBeat recorded 5 mentions for Valneva and 4 mentions for Ikena Oncology. Valneva's average media sentiment score of 0.40 beat Ikena Oncology's score of 0.00 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ikena Oncology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, VALN or IKNA? Ikena Oncology has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$158.54M2.05-$109.78M-$0.13-30.77Ikena Oncology$659K134.01-$68.17M-$1.23-1.49 Is VALN or IKNA more profitable? Ikena Oncology has a net margin of 0.00% compared to Valneva's net margin of -4.35%. Valneva's return on equity of -3.93% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% Ikena Oncology N/A -36.88%-33.08% Which has more volatility & risk, VALN or IKNA? Valneva has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Do insiders and institutionals hold more shares of VALN or IKNA? 11.4% of Valneva shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in VALN or IKNA? Valneva received 2 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 60.38% of users gave Valneva an outperform vote while only 60.00% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3260.38% Underperform Votes2139.62% Ikena OncologyOutperform Votes3060.00% Underperform Votes2040.00% Do analysts recommend VALN or IKNA? Valneva currently has a consensus price target of $18.50, indicating a potential upside of 362.50%. Ikena Oncology has a consensus price target of $3.00, indicating a potential upside of 63.93%. Given Valneva's stronger consensus rating and higher probable upside, equities research analysts clearly believe Valneva is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryValneva beats Ikena Oncology on 13 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.31M$2.92B$5.16B$9.10BDividend YieldN/A1.91%5.12%4.26%P/E Ratio-1.4946.1187.5117.12Price / Sales134.01407.151,136.45119.65Price / CashN/A174.7643.2337.85Price / Book0.523.874.784.77Net Income-$68.17M-$42.00M$120.55M$225.50M7 Day Performance13.66%-2.89%-1.64%-1.29%1 Month Performance7.02%1.36%14.04%0.45%1 Year Performance-19.03%16.74%28.88%15.38% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology2.0292 of 5 stars$1.67+7.7%$3.00+79.6%-31.4%$80.59M$659,000.00-1.3670Analyst ForecastNews CoverageGap UpTrading HaltedHigh Trading VolumeVALNValneva2.1641 of 5 stars$3.81-3.1%$18.50+385.6%-60.1%$309.56M$165.52M-30.23700News CoverageHigh Trading VolumeLRMRLarimar Therapeutics1.5619 of 5 stars$4.83-21.7%$20.43+323.0%-6.3%$308.20MN/A-3.5630High Trading VolumeFHTXFoghorn Therapeutics2.8958 of 5 stars$5.51+4.0%$15.20+175.9%-23.5%$306.32M$25.52M-2.63120High Trading VolumeCCCCC4 Therapeutics2.048 of 5 stars$4.31-1.6%$10.00+132.0%-11.4%$304.24M$33.67M-2.58150IMMPImmutep1.4382 of 5 stars$2.08-4.6%$8.50+308.7%-12.9%$302.56M$5.14M0.002,021FDMT4D Molecular Therapeutics2.7774 of 5 stars$6.48-0.3%$42.13+550.1%-69.5%$299.56M$17,000.00-2.28201CMPSCOMPASS Pathways2.8388 of 5 stars$4.33+2.6%$33.60+676.0%-54.6%$296.26MN/A-1.92120Positive NewsBNTCBenitec Biopharma3.59 of 5 stars$12.58+6.9%$24.43+94.2%+241.6%$292.11M$80,000.000.0020Gap UpACIUAC Immune2.3685 of 5 stars$2.92-1.0%$12.00+311.0%-38.1%$288.91M$40.97M-6.35140Positive NewsAMLXAmylyx Pharmaceuticals4.2559 of 5 stars$4.18+1.5%$7.33+75.4%-72.1%$286.53M$196.49M-1.08200Positive News Related Companies and Tools Related Companies VALN Competitors LRMR Competitors FHTX Competitors CCCC Competitors IMMP Competitors FDMT Competitors CMPS Competitors BNTC Competitors ACIU Competitors AMLX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IKNA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
